PSC Australia
  • Home
  • PSC
  • Resources
  • PSC Research
  • Rare Diseases
  • Contact Us

Scientific Research
This page is in a'blog' format with the latest scientific PSC research identified by Google Scholar, Readbyqmx.com and other sources added regularly.

Variation in Microbiome Composition and Stability for a Vancomycin Treated Primary Sclerosing Cholangitis Patient with Ulcerative Colitis Compared with Controls 

12/16/2015

0 Comments

 
Abstract


The bacterial composition of the human intestines contributes to much more than just digestion. In the inflammatory autoimmune conditions primary sclerosing cholangitis (PSC) and ulcerative colitis (UC), the microbiome may be, in some cases, a factor. To gain a better understanding of the composition and stability of the microbiome in a patient treated with vancomycin for PSC ... Please click here to read the full research article

Dubrovsky, Alanna (2015) "Variation in Microbiome Composition and Stability for a Vancomycin Treated Primary Sclerosing Cholangitis Patient with Ulcerative Colitis Compared with Controls," Symposium: Vol. 2: Iss. 1, Article 6.
Available at:
h p://digitalcommons.calpoly.edu/symposium/vol2/iss1/6 


0 Comments

Variation in Microbiome Composition and Stability for a Vancomycin Treated Primary Sclerosing Cholangitis Patient with Ulcerative Colitis Compared with Controls 

11/29/2015

0 Comments

 
Abstract 

The bacterial composition of the human intestines contributes to much more than just digestion. In the in- ammatory autoimmune conditions primary sclerosing cholangitis (PSC) and ulcerative colitis (UC), the microbiome may be, in some cases, a factor. To gain a better understanding of the composition and stability of the microbiome in a patient treated with vancomycin for PSC, terminal restriction fragment (TRF) analysis was performed on 13 controls and 1 patient, and 16s rRNA microbiome composition analyses were performed on 1 patient and 3 controls. Results showed similar levels of stability with surprising di erences in composition. Please click here to read the full text of the article




Dubrovsky, Alanna (2015) Symposium: Vol. 2: Iss. 1, Article 6.
DOI: 10.15368/symp.2015v2n1.2
Available at:
h p://digitalcommons.calpoly.edu/symposium/vol2/iss1/6 



0 Comments

Successful Treatment of Recurrent Primary Sclerosing Cholangitis after Orthotopic Liver Transplantation with Oral Vancomycin

9/17/2015

0 Comments

 
Yinka K. Davies,  Cynthia J. Tsay,  Dario V. Caccamo,  Kathleen M. Cox, Ricardo O. Castillo, Kenneth L. Cox

Abstract:
Primary sclerosing cholangitis (PSC) is a progressive, cholestatic disease of the liver that is marked by inflammation of the bile ducts and damage to the hepatic biliary tree. Approximately 60–70% of patients also have inflammatory bowel disease and progression of PSC can lead to ulcerative colitis and cirrhosis of the liver. Due to limited understanding of the etiology and mechanism of PSC, the only existing treatment option is orthotopic liver transplantation (OLT); however, recurrence of PSC, after OLT is estimated to be between 5% and 35%. We discuss the successful treatment of a pediatric patient, with recurrent PSC, after OLT with oral Vancomycin ... Please click here to read the full article.

Case Reports in Transplantation
Volume 2013 (2013), Article ID 314292, 5 pages
http://dx.doi.org/10.1155/2013/314292

0 Comments

Primary sclerosing cholangitis during childhood and adolescence

7/9/2014

0 Comments

 
Primary sclerosing cholangitis during childhood and adolescence

Tamir Miloh and Pinar Bulut, Clinical Liver Disease Special Issue: Liver Disease in Children
Volume 2, Issue 5, pages 215–218, October 2013

Primary sclerosing cholangitis (PSC) is an idiopathic, chronic hepatobiliary disorder characterized by inflammation with progressive obliterative fibrosis and focal dilatation of the intrahepatic and/or extrahepatic bile ducts which leads to biliary cirrhosis and end-stage liver disease.[1] The clinical features of PSC in children and adolescents are summarized in Table 2. PSC is more common in Caucasian male patients and has a strong association with inflammatory bowel disease (IBD), especially ulcerative colitis. In children, secondary causes of sclerosing cholangitis include Langerhans cell histiocytosis, immunodeficiencies, and cystic fibrosis. The incidence of PSC in children is 0.23 cases per 100,000 person-years compared with 1.11/100,000 in adults.[2] . . . Please click here to access the full text of this article. There is also a video presentation and an interview with the authors

0 Comments

Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study

7/8/2014

0 Comments

 
Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study

J. H. Tabibian, E. Weeding, R. A. Jorgensen, J. L. Petz, J. C. Keach, J. A. Talwalkar, K. D. Lindor
Alimentary Pharmacology & Therapeutics Volume 37, Issue 6, pages 604–612, March 2013

Summary

Background
Emerging data suggest that oral antibiotics may have therapeutic effects in primary sclerosing cholangitis (PSC), but published studies are limited.

Aims
To investigate the safety and efficacy of oral vancomycin and metronidazole in patients with PSC.

Methods
Thirty-five patients with PSC were randomised in a double-blind manner into four groups: vancomycin 125 mg or 250 mg four times/day, or metronidazole 250 mg or 500 mg three times/day for 12 weeks. The primary endpoint was decrease in alkaline phosphatase (ALK) at 12 weeks. Secondary end points included serum bilirubin and Mayo PSC risk score; pruritus; and adverse effects (AEs). Nonparametric tests were used for analysis.

Results
The primary endpoint was reached in the low-dose (−43% change in ALK, P = 0.03) and high-dose (−40%, P = 0.02) vancomycin groups, with two patients in the former experiencing ALK normalisation . . . Please click here to read the full text of this article

Note: The reference list of the article provides links to other full text articles.
0 Comments

Successful Treatment of Recurrent Primary Sclerosing Cholangitis after Orthotopic Liver Transplantation with Oral Vancomycin

7/8/2014

0 Comments

 
Successful Treatment of Recurrent Primary Sclerosing Cholangitis after Orthotopic Liver Transplantation with Oral Vancomycin


Yinka K. Davies, Cynthia J. Tsay, Dario V. Caccamo, Kathleen M. Cox, Ricardo O. Castillo, and Kenneth L. Cox
Case Reports in Transplantation
Volume 2013 (2013), Article ID 314292, 5 pages
http://dx.doi.org/10.1155/2013/314292

Abstract

Primary sclerosing cholangitis (PSC) is a progressive, cholestatic disease of the liver that is marked by inflammation of the bile ducts and damage to the hepatic biliary tree. Approximately 60–70% of patients also have inflammatory bowel disease and progression of PSC can lead to ulcerative colitis and cirrhosis of the liver. Due to limited understanding of the etiology and mechanism of PSC, the only existing treatment option is orthotopic liver transplantation (OLT); however, recurrence of PSC, after OLT is estimated to be between 5% and 35%. We discuss the successful treatment of a pediatric patient, with recurrent PSC, after OLT with oral Vancomycin ... Please click here to access to the full text of this article
0 Comments

    Research

    Every effort is taken to ensure the research presented is from reputable sources. 

    In order to ensure that copyright is not breached, only a small portion of the abstract is provided here. Clicking on the title will take you to the original journal, or site, where the abstract has been published. Most times only an abstract of an article is available as subscriptions are usually required. Occasionally a full text is made freely available.

    RSS Feed

    News & Updates Blog
    Glossary

    Archives

    December 2016
    September 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    August 2014
    July 2014
    June 2014
    April 2014
    March 2014


    Categories

    All
    Adolescence
    Adults
    Antibiotic
    Australia
    Australian
    Autoimmune Diseases
    Autoimmune Hepatitis
    Bezafibrate
    Bile Leak
    Biliary Strictures
    Cancer
    CCA Risk
    Children
    Cholangiocarcinoma
    Cholangitis
    Cholectomy
    Cholestatic Liver Disease
    Colectomy
    Colorectal Cancer
    Consensus Statement
    Crohn's Disease
    Diagnosis
    Drug Therapy
    Endoscopy
    Environmental Factors
    ERCP
    Fibroscan
    Genetics
    Genomes
    Genotypes
    Hepatic Cholestasis
    HLA
    IBD
    IgE Levels
    IgG4
    Inflammatory Bowel Disease
    Itching
    Leaky Gut
    Liver
    Liver Tests
    Liver Transplant
    Living Donor
    Management Of PSC
    MELD Score
    Microbiome
    Organ Donation
    Outcomes
    Paediatric Patients
    Paediatric PSC
    Patient And Graft Survival
    Pets
    Population
    Prognosis
    Pruritus
    PSC
    PSC/AIH
    Quality Of Life
    Questionnaire
    Recurrent PSC
    RPSC
    Sclerosing Cholangitis
    Scoring Systems
    Screening
    Staging
    Staging Systems
    Stem Cells
    Stenosis
    Terminal Restriction Fragment (TRF)
    Treatment
    Ulcerative Colitis
    Ultrasound
    Ultrasound Elastography
    Ursodeoxycholic Acid
    Vancomycin


    RSS Feed


    Page created 09.03.2014
    Updated: 09.04.2014
Disclaimer:  The information presented on this website is intended for information and educational purposes only, and is not intended to be a substitute for medical advice or information in any way. The information is not written by a medical practitioner, and as such it should never be used for diagnostic, treatment or management purposes. If you have questions regarding your medical needs, always seek the advice of your doctor, specialist or other appropriate and qualified health care professional.
This is a non-commercial website, designed and developed to provide relevant information to people living with Primary Sclerosing Cholangitis.
Wallpaper by Gaiam   www.gaiam.com.au

Full Disclaimer
Medical Disclaimer


Privacy & Cookie Policy


Powered by Create your own unique website with customizable templates.

BACK TO TOP

PSC-Australia.com.au
©2014 Health & Education Services | All Rights Reserved

© DivTag Templates Ltd | All Rights Reserved